FDA Expands Approval of Inhaled Insulin for Children: A…

FDA Expands Approval of Inhaled Insulin for Children: A New Option for Type 1 Diabetes Care Published by TALMedora Editorial | Endocrinology | Diabetes Care | Paediatrics For many children living with type 1 diabetes, managing blood sugar means multiple insulin injections every single day. From classrooms and sports fields to birthday parties and family outings, insulin therapy often becomes a constant part of daily life. Now, a newly approved inhaled insulin may offer some families a less invasive alternative. The U.S. Food and Drug Administration (FDA) has expanded approval of Afrezza, an ultra-rapid acting inhaled insulin, for children and adolescents aged six years and older with diabetes. The decision marks an important development in pediatric diabetes care, providing a needle-free mealtime insulin option for selected patients. Type 1 diabetes occurs when the body's immune system attacks insulin-producing cells in the pancreas. Without insulin, blood sugar levels rise to dangerous levels, making lifelong insulin replacement essential. While modern technologies such as insulin pumps and continuous glucose monitors have transformed diabetes management, many children still require multiple daily injections. For some families, this can create physical discomfort, treatment fatigue, and emotional stress. An inhaled insulin option may help reduce some of these challenges. Unlike traditional rapid-a